title: Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 2. Treatment of some ROS- and age-related diseases (heart arrhythmia, heart infarctions, kidney ischemia, and stroke).
abstract: Effects of 10-(6'-plastoquinonyl) decyltriphenylphosphonium (SkQ1) and 10-(6'-plastoquinonyl) decylrhodamine 19 (SkQR1) on rat models of H2O2- and ischemia-induced heart arrhythmia, heart infarction, kidney ischemia, and stroke have been studied ex vivo and in vivo. In all the models listed, SkQ1 and/or SkQR1 showed pronounced protective effect. Supplementation of food with extremely low SkQ1 amount (down to 0.02 nmol SkQ1/kg per day for 3 weeks) was found to abolish the steady heart arrhythmia caused by perfusion of isolated rat heart with H2O2 or by ischemia/reperfusion. Higher SkQ1 (125-250 nmol/kg per day for 2-3 weeks) was found to decrease the heart infarction region induced by an in vivo ischemia/reperfusion and lowered the blood levels of lactate dehydrogenase and creatine kinase increasing as a result of ischemia/reperfusion. In single-kidney rats, ischemia/reperfusion of the kidney was shown to kill the majority of the animals in 2-4 days, whereas one injection of SkQ1 or SkQR1 (1 micromol/kg a day before ischemia) saved lives of almost all treated rats. Effect of SkQR1 was accompanied by decrease in ROS (reactive oxygen species) level in kidney cells as well as by partial or complete normalization of blood creatinine and of some other kidney-controlled parameters. On the other hand, this amount of SkQ1 (a SkQ derivative of lower membrane-penetrating ability than SkQR1) saved the life but failed to normalize ROS and creatinine levels. Such an effect indicates that death under conditions of partial kidney dysfunction is mediated by an organ of vital importance other than kidney, the organ in question being an SkQ1 target. In a model of compression brain ischemia/reperfusion, a single intraperitoneal injection of SkQR1 to a rat (1 micromol/kg a day before operation) effectively decreased the damaged brain area. SkQ1 was ineffective, most probably due to lower permeability of the blood-brain barrier to this compound.
authors.affiliation: Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.
authors.forename: L E
authors.initials: LE
authors.lastname: Bakeeva
authors.forename: I V
authors.initials: IV
authors.lastname: Barskov
authors.forename: M V
authors.initials: MV
authors.lastname: Egorov
authors.forename: N K
authors.initials: NK
authors.lastname: Isaev
authors.forename: V I
authors.initials: VI
authors.lastname: Kapelko
authors.forename: A V
authors.initials: AV
authors.lastname: Kazachenko
authors.forename: V I
authors.initials: VI
authors.lastname: Kirpatovsky
authors.forename: S V
authors.initials: SV
authors.lastname: Kozlovsky
authors.forename: V L
authors.initials: VL
authors.lastname: Lakomkin
authors.forename: S B
authors.initials: SB
authors.lastname: Levina
authors.forename: O I
authors.initials: OI
authors.lastname: Pisarenko
authors.forename: E Y
authors.initials: EY
authors.lastname: Plotnikov
authors.forename: V B
authors.initials: VB
authors.lastname: Saprunova
authors.forename: L I
authors.initials: LI
authors.lastname: Serebryakova
authors.forename: M V
authors.initials: MV
authors.lastname: Skulachev
authors.forename: E V
authors.initials: EV
authors.lastname: Stelmashook
authors.forename: I M
authors.initials: IM
authors.lastname: Studneva
authors.forename: O V
authors.initials: OV
authors.lastname: Tskitishvili
authors.forename: A K
authors.initials: AK
authors.lastname: Vasilyeva
authors.forename: I V
authors.initials: IV
authors.lastname: Victorov
authors.forename: D B
authors.initials: DB
authors.lastname: Zorov
authors.forename: V P
authors.initials: VP
authors.lastname: Skulachev
mesh_terms: D000375:Aging; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D001692:Biological Transport; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D002478:Cells, Cultured; D006801:Humans; D066298:In Vitro Techniques; D007674:Kidney Diseases / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008928:Mitochondria / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D010971:Plastoquinone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism*; D015424:Reperfusion; D012235:Rhodamines / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use
chemical_list: C534903:10-(6'-plastoquinonyl) decylrhodamine 19; C532038:10-(6'-plastoquinonyl)decyltriphenylphosphonium; D000975:Antioxidants; D017382:Reactive Oxygen Species; D012235:Rhodamines; D010971:Plastoquinone